|
ドイハラ ヒロヨシ
Hiroyoshi Doihara
土井原 博義 所属 川崎医科大学 医学部 臨床医学 総合外科学 職種 特任教授 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Optimizing the timing of 3.6 mg Pegfilgrastim Administration for Dose-Dense Chemotherapy in Japanese Patients with Breast Cancer. |
| 掲載誌名 | 正式名：Acta medica Okayama 略 称：Acta Med Okayama ISSNコード：0386300X/0386300X |
| 掲載区分 | 国外 |
| 巻・号・頁 | 75(3),pp.357-362 |
| 著者・共著者 | Takabatake Daisuke, Kajiwara Yukiko, Ohtani Shoichiro, Suzuki Yoko, Yamamoto Mari, Kubo Shinichiro, Ikeda Masahiko, Takahashi Mina, Hara Fumikata, Aogi Kenjiro, Ohsumi Shozo, Ogasawara Yutaka, Nishiyama Yoshitaka, Hikino Hajime, Matsuoka Kinya, Shien Tadahiko, Taira Naruto, Doihara Hiroyoshi |
| 発行年月 | 2021/06 |
| 概要 | Perioperative dose-dense chemotherapy (DDCT) with pegfilgrastim (Peg) prophylaxis is a standard treatment for high-risk breast cancer. We explored the optimal timing of administration of 3.6 mg Peg, the dose approved in Japan. In the phase II feasibility study of DDCT (adriamycin+cyclophosphamide or epirubicin+cyclophosphamide followed by paclitaxel) for breast cancer, we investigated the feasibility, safety, neutrophil transition, and optimal timing of Peg treatment by administering Peg at days 2, 3, and 4 post-chemotherapy (P2, P3, and P4 groups, respectively). Among the 52 women enrolled, 13 were aged > 60 years. The anthracycline sequence was administered to P2 (n=33), P3 (n=5), and P4 (n=14) patients, and the taxane sequence to P2 (n=38) and P3 (n=6) patients. Both sequences showed no interaction between Peg administration timing and treatment discontinuation, treatment delay, or dose reduction. However, the relative dose intensity (RDI) was significantly different among the groups. The neutrophil count transition differed significantly among the groups receiving the anthracycline sequence. However, the neutrophil count remained in the appropriate range for both sequences in the P2 group. The timing of Peg administration did not substantially affect the feasibility or safety of DDCT. Postoperative day 2 might be the optimal timing for DDCT. |
| DOI | 10.18926/AMO/62231 |
| PMID | 34176940 |